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Identity 




This gene can be found at chromosome 11p15.4, and 
contains 6 exons spanning 4,24 kb. 
Transcription 
MMP-26 has 998 mRNA nucleotides and no 
transcript variant. The transcription of this gene is 
regulated by three elements, estrogen-responsive 
element (ERE), T-cell factor-4 (TCF-4), and activator 
protein-1 (AP-1), due to the highly unusual poly (A) 
site located upstream of its promoter. Further 
regulation of TCF-4 is accomplished by the β-
catenin/epithelial-cadherin (E-cadherin) pathway and 
suggests that MMP-26 is specifically expressed in 
cells of epithelial origin. The gene for MMP-26 has 
one transcriptional start  
site and a consensus TATA-box, located 35 and 60 




MMP-26 is the smallest member of the matrix 
metalloproteinase (MMP) family of zinc-dependent 
endopeptidases. Synthesized as a zymogen, the 
nascent form is composed of three domains: (1) "pre" 
domain, N-terminal signal sequence, which directs 
the protein into the endoplasmic reticulum; (2) an 
unconventional "pro" domain, which maintains 
enzyme-latency; and (3) a catalytic domain, which 
contains the conserved zinc-binding region for 
proteolysis. 
The MMP-26 pro-enzyme starts at residue 18, with 
the full length of the protein spanning 261 amino 
acids. 
The full-length enzyme has a theoretical molecular 
weight of 28 kDa that is truncated to 19 kDa upon 
activation (cleavage of the pro-domain). 
 
Containing 6 exons spanning 4,24 kb, MMP-26 is found at chromosome 11p15.4. 
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Schematic of MMP-26 (wild type). Pre-, signal peptide of MMP-26 (residues 1-17); Pro-, pro-peptide of MMP-26 (residues 18-90); 
and Cat-, catalytic domain of MMP-26 (residues 91-261). 
 
Among the MMPs, only MMP-26 has a "cysteine-
switch" sequence that contains a histidine residue 
instead of the usual arginine residue 
(PH81CGVPDGSD) in the pro-peptide domain and 
has a zinc-binding motif (V205ATHEIGHSLGLQH) 
in the catalytic domain. Additionally, MMP-26 lacks 
the hinge region and hemopexin-like domain that is 
common to other family members. MMP-26 has two 
calcium binding sites: (1) a high-affinity site required 
for enzymatic activity, protein stability, and 
protection from denaturation; and (2) a low-affinity 
site primarily important for protein folding, tertiary 
structure, and native conformation. The protein also 
contains three possible N-linked glycosylation sites 
(N64, N133, N221). 
Expression 
MMP-26 has been found strictly expressed in normal 
tissues of the placenta and moderately expressed in 
the uterus. However, MMP-26 expression is also 
associated with human cancer cells, especially in 
estrogen receptor (ER)-α positive breast cancer cells 
and cancerous cells of the ovary and endometrium. 
The expression of MMP-26 in cancerous breast, 
colon, lung, brain, head and neck, prostate, and 
melanoma tissues was significantly elevated when 
compared with parallel normal tissues, while not 
significantly elevated in kidney cancer, ovarian 
cancer, and non-Hodgkin's lymphoma. 
Localisation 
Intracellular (endoplasmic reticulum-retained), 
secreted, pericellular, and extracellular. 
Function 
MMP-26 cleaves many extracellular matrix and 
plasma proteins including: (1) amino terminus of 
estrogen receptor β; (2) α1-antitrypsin; (3) insulin-
like growth factor-binding protein 1 (IGFBP-1); (4) 
fibronectin; (5) vitronectin; (6) fibrinogen; (7) 
gelatins of types I-IV; (8) gelatinase B (MMP-9); (9) 
α2-macroglobulin; and (10) type IV collagen. MMP-
26 digests one peptide substrate of tumor necrosis 
factor-α converting enzyme (TACE/ADAM17) and 
four peptide substrates of MMPs. MMP-26 activates 
MMP-9 by cleavage of the pre-proenzyme (Ala93-
Met94 site) and produces activated MMP-9 products 
that are more stable than those activated by MMP-7. 
MMP-26 also forms a complex with tissue inhibitors  
of metalloproteinases 4 (TIMP-4). MMP-26 is 
inhibited by GM6001 and TIMPs -2 (1,60 nM) and -4 
(0,62 nM), exhibiting an inhibition profile most 
similar to those of MMPs with intermediate S1' 
pockets (His-233). MMP-26 can auto-digest itself 
during the folding process and is also capable of self-
activation with its catalytic activity affected by 
detergents. 
Homology 
Belongs to matrix metalloproteinase (MMP) family 
and exhibits a similar domain structure to that of 
matrilysin (MMP-7) but is most homologous to 




MMP-26 is not expressed in normal mammary 
epithelium, is strongly upregulated in ductal 
carcinoma in situ (DCIS), and decreases throughout 
further disease progression (stages I to III). Co-
expression of MMP-26 and TIMP-4 or MMP-9 has 
been detected in DCIS. Estrogen receptor-β (ER-β), 
not ER-α, is a substrate of MMP-26 in vivo and in 
vitro, indicating a novel regulation loop between 
estrogen and ER and modification of the ER-α/ER-β 
ratio. Additionally, silencing MMP-26 expression in 
the human breast cancer cell line MDA-MB-231 up-
regulated the expression of five proteins (heat shock 
protein 90, glucose-regulated protein 78, annexin V, 
tropomyosin, peroxiredoxin II) and down-regulated 
the expression of four proteins (α-tubulin, cystatin 
SA-III, breast cancer metastasis suppressor 1 
(BRMS1), and β-actin). 
Prognosis 
MMP-26 expression is associated with ER+ human 
breast cancer and has positive correlation with patient 
survival in DCIS. 
Endometrial cancer, ovarian cancer 
Note 
MMP-26 mRNA is localized in the epithelial 
component of normal, hyperplastic, premalignant, 
and malignant samples of endometrial tissue and in 
situ hybridization indicates maximal levels in normal 
tissue (midcycle) and in endometrial hyperplasia 
(with and without atypia). Endometrial carcinomas 
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exhibit greater expression compared to benign 
endometrium from the postmenopausal period, but 
not from the secretory phase of the menstrual cycle. 
Expression progressively decreases with loss of 
histological differentiation in malignant samples. 
Increased staining intensity correlates with grade III 
tumors and with the depth of myometrial invasion in 
tumors histologically characterized as endometrioid 
adenocarcinoma. Relating to ovarian cancer, MMP-
26 is expressed in normal tissue as well as ovarian 
tumors with expression increasing with increased 
tumor stage. Invading ovarian tumor cells display the 
strongest expression of MMP-26, and progression of 
ovarian cancer is correlated with MMP-26 co-
expression with TIMP-3, and TIMP-4. 
Prostate cancer, prostatitis, benign 
prostate hyperplasia (BPH), and high-
grade prostatic intraepithelial 
neoplasia (HGPIN) 
Note 
Protein levels in human prostate carcinomas from 
multiple patients were significantly higher than those 
in prostatitis, benign prostate hyperplasia (BPH), and 
normal prostate glandular tissue.  
MMP-26 and TIMP-4 expression was found higher in 
HGPIN and cancer when compared to non-neoplastic 
acini. 
Prognosis 
For the progression of high-grade prostatic 
intraepithelial neoplasia (HGPIN) to invasive 
adenocarcinoma, it is crucial to disrupt the continui y 
of the basal cell layer and basement membrane.  
MMP-26 may play an integral role during this 
conversion and may serve as a marker for earlier 
diagnoses. 
Oncogenesis 
MMP-26, by cleaving basement membrane proteins 
and activating pro-MMP-9, promotes invasion of 
human prostate cancer cells. 
Squamous cell carcinomas (SCC) 
Note 
Squamous cell cancers can be recognized as an 
uncontrolled wound healing process.  
MMP-26 expression is present in migrating 
keratinocytes (KC) of healing wounds compared with 
normal intact skin cells.  
Furthermore, expression was not found to be present 
in proliferating Ki-67-positive KC but co-localized 
with tumor suppressor p16. MMP-26 was also 
detected in squamous cell cancer (SCC) grades I and
II, but was not present in grade III.  
In another study, high-grade SCC shows a 
statistically significant higher expression of MMP-26 
and is associated with morphological scores of 
malignancy.  
MMP-26 is suggested to contribute to more 
aggressive behavior of SCCs in organ transplant 
recipients.  
In SCC of the esophagus (ESCC), MMP-26 was 
upregulated in incipient invasion and its expression 
associated with regions of low differentiation being 
more sporadic at the invasive front. MMP-26, nuclear 
β-catenin, and active MMP-9 expression correlate in 
ESCC tissue, which was found significantly 
correlated with depth of invasion, lymph node and 
distant metastasis, advances in pTNM stage, and 
recurrence. 
Disease 
Oral squamous cell carcinomas, Esophageal 
squamous cell carcinoma. 
Prognosis 
Lack of MMP-26 in SCC could be a marker of 
aggressive growth. Another report questions the 
usefulness of MMP-26 as an indicator of the 
metastatic potential of SCCs of the tongue.  
MMP-26 positive ESCC patients showed 
significantly shorter overall and disease-free survival 




Expression of MMP-26 is significantly higher in non-
small cell lung cancer (NSCLC) than in atypical 
hyperplasia and normal lung tissue and correlates 
with carcinogenesis, lymph node metastasis, clinical 
stage, and prognosis. Silencing of MMP-26 
significantly reduced invasiveness of A549 cells in 
Transwell invasion assays, suggesting MMP-26 to 
play an important role in local invasion, at least in 
part through coordination with MMP-9. 
Disease 
Non-small Cell Lung Cancer (NSCLC). 
Prognosis 
MMP-26 may be used as a tumor marker in 
monitoring progression and predicting prognosis of 
NSCLC since disease-free and overall survival are 
shorter in NSCLC patients with high expression of 
MMP-26. 
Glioblastoma multiforme (brain tumor) 
Note 
Overexpression of MMP-26 in U251 cells resulted in 
a significantly higher cell-spreading ratio when 
compared to parental U251 cells.  
The relative migration distance on Matrigel was also 
significantly greater. Boyden Chamber assays further 
indicated an enhanced invasive ability of MMP-26 
overexpressed U251 cells.  
The microvessel density of tumor tissues derived 
from MMP-26 transfected cells was also greater 
when compared to the parental cell line. 
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Oncogenesis 
MMP-26 contributes to U251 cell invasion and 
migration in vitro and plays an important role in local 
invasion and angiogenesis. 
Merkel cell carcinoma (cutaneous 
tumor) 
Note 
MMP-26 expression was positive in stromal cells and
was associated with tumors greater than or equal to 2-
cm in diameter. 
Prognosis 
Stroma expression is associated with larger tumors 
with poor prognosis. 
Pancreatic cancer, pancreatic 
adenocarcinoma 
Note 
Patients with metastatic cancer cells in lymph nodes 
had increased expression of MMP-26 in tumor 
samples. In a pancreatic cell line (PANC-1) MMP-26 
was neither expressed basally nor induced by TNF-α, 
TGFβ1, EGF, or interferon γ. 
Colon cancer 
Note 
Unlike classical MMPs, MMP-26 is expressed in the 
normal intestine and was detected in migrating 
enterocytes. Staining for MMP-26 revealed a 
meshwork-like pattern between cancer islets and 
suggested to be involved in enterocyte migration. 
To be noted 
Note 
No intracellular substrates of MMP-26 identified in 
disease with its high expression except for ER-β in 
breast cancer. No homologous analog of MMP-26 
found in rodents. 
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